A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

This study is testing a new medication called neladalkib for people with advanced solid tumors or non-small cell lung cancer that have a specific genetic change called 'ALK.' The goal is to see if this new drug is safe and effective at shrinking or controlling these types of cancer.

You may be eligible if you are 18 or older and have been diagnosed with an advanced solid cancer or lung cancer that tests positive for the ALK gene mutation. You must not be currently receiving other cancer treatments or participating in another drug study.

Participants will take the study drug neladalkib, and researchers will monitor your health closely to see how your body reacts to the treatment. Some participants may also take other common medications—like those for relaxation or blood sugar—to help researchers understand how the study drug interacts with them.

This study is currently recruiting volunteers at locations in Orange, Sacramento, and Stanford, California. Please talk to your doctor to see if one of these centers is the right fit for your care.